Osteoporosis and bone health at menopause
One in two women over 50 will have a fracture related to osteoporosis. The bone loss that causes it begins in perimenopause — silently, with no symptoms — at up to 4% per year. The good news: it is largely preventable with early action. Rose covers the full picture: mechanisms, risk factors, DEXA scanning, and every evidence-graded intervention.
Rose
"Bone loss is the silent menopause consequence — there are no symptoms until a fracture happens. What strikes me most in researching this is how much of it is preventable with early action, and how few women are told about the five-year window of fastest loss around menopause when intervention matters most. HRT, resistance training, vitamin D optimised to the right level, adequate protein — these are not complicated. They just need to start before the loss is already significant."
The scale of this
1 in 2
women over 50 will have an osteoporotic fracture
4%
annual bone loss in the first 5 years after menopause
50%
reduction in hip fracture risk with HRT in large studies
Key takeaways
✓Bone loss begins in perimenopause — silently, with no symptoms. The five years around menopause are the fastest loss phase.
✓Estrogen is the primary regulator of bone remodelling in women — its loss unleashes osteoclast activity that osteoblasts cannot match
✓HRT reduces hip fracture risk by 25-30% and vertebral fracture by 35-40% — one of the strongest evidence bases for any menopause intervention
✓Resistance training with progressive loading is the most powerful non-hormonal bone stimulus — endurance exercise alone is not sufficient
✓Vitamin D must be optimised to 60-80 ng/mL for calcium absorption — standard dosing (400-800 IU) rarely achieves this
✓Request a DEXA scan at perimenopause — it is the only way to know your bone density before fractures occur
✓The FRAX tool calculates your 10-year fracture risk and should inform treatment decisions alongside DEXA
How bone loss happens — four mechanisms
🦴
Bone is not static — it is constantly remodelled
Bone is living tissue, continuously broken down by osteoclasts and rebuilt by osteoblasts in a process called remodelling. In healthy adults, resorption (breakdown) and formation are balanced. Estrogen is the primary regulator of this balance in women — it suppresses osteoclast activity and supports osteoblast function. When estrogen falls at menopause, osteoclast activity increases dramatically and is no longer balanced by osteoblast formation. The result: net bone loss at a rate of 2-4% per year in the first five years after menopause — faster than at any other point in adult life.
📉
Peak bone mass determines your starting point
Women reach peak bone mass between ages 25-30. The amount of bone accumulated before this peak determines the starting density from which menopause-related loss begins. Women who had poor calcium and vitamin D intake in childhood and adolescence, who were underweight, who smoked, or who had hormonal disruptions (athletic amenorrhoea, eating disorders) reach peak bone mass with a lower baseline — meaning the same percentage loss puts them into the osteopenic or osteoporotic range sooner.
⏱️
The five-year window of fastest loss
The most rapid phase of bone loss occurs in the 5 years around menopause — both late perimenopause and early postmenopause. Women lose 10-20% of their bone density in this window. This is the period when intervention has the most impact — HRT, vitamin D, calcium, and resistance training started in perimenopause protect bone during its most vulnerable phase. Waiting until a fracture or a low DEXA score to act means years of preventable bone loss have already occurred.
🔬
Trabecular bone is most vulnerable first
Bone has two types: cortical (the dense outer shell) and trabecular (the spongy inner lattice, particularly abundant in the spine and wrist). Trabecular bone has higher surface area and higher metabolic activity — it responds most rapidly to estrogen loss. Vertebral fractures (compression fractures of the spine) and wrist fractures are therefore the earliest osteoporotic fractures, often before hip fracture risk becomes significant. A woman may have significant vertebral bone loss with no symptoms — height loss and postural changes (the "dowager's hump") are often the first visible signs.
Risk factors — what increases your bone loss risk
| Risk factor |
Impact |
Why |
| Early menopause (before 45) |
High |
More years of estrogen deficiency |
| Surgical menopause (oophorectomy) |
High |
Abrupt estrogen loss, most severe bone loss |
| Family history of osteoporosis |
High |
Strong genetic component to bone density |
| Low BMI (under 19) |
High |
Less bone-protective mechanical loading and less estrogen from fat tissue |
| Smoking |
High |
Direct toxic effect on osteoblasts, reduces estrogen metabolism |
| Corticosteroid use (>3 months) |
High |
Most common drug cause of secondary osteoporosis |
| Low calcium / vitamin D intake |
Moderate |
Essential cofactors for bone mineralisation |
| Excessive alcohol (>2 units daily) |
Moderate |
Reduces osteoblast activity and calcium absorption |
| History of amenorrhoea or eating disorder |
Moderate |
Years of reduced bone-protective estrogen |
| Sedentary lifestyle |
Moderate |
Mechanical loading is required to maintain bone density |
| Coeliac disease / malabsorption |
Moderate |
Impairs calcium and vitamin D absorption |
| Rheumatoid arthritis |
Moderate |
Inflammatory cytokines increase osteoclast activity |
DEXA scanning — the essential test
What DEXA measures and what the T-score means
Dual-energy X-ray absorptiometry (DEXA) is the gold-standard test for bone density. It measures bone mineral density (BMD) at the lumbar spine and hip — the sites most clinically relevant for osteoporotic fracture — and expresses the result as a T-score: the number of standard deviations above or below the peak bone mass of a young adult woman.
T-score above -1.0bone density within the normal range for young adults
T-score -1.0 to -2.5below normal but not yet osteoporosis. Important intervention window.
T-score below -2.5osteoporosis. Fracture risk significantly elevated.
T-score below -2.5 with a fragility fracturesevere osteoporosis.
DEXA should be requested at perimenopause — particularly for women with risk factors. In the UK, DEXA is not routinely offered on the NHS at perimenopause without additional risk factors, but it should be requested when early menopause, surgical menopause, corticosteroid use, or strong family history is present. Private DEXA is available for approximately £50-100.
💡
FRAX — the fracture risk calculator
The FRAX tool (available at sheffield.ac.uk/FRAX) calculates your 10-year probability of a major osteoporotic fracture based on clinical risk factors — with or without DEXA results. It is used by GPs and specialists to guide treatment decisions. Running your own FRAX gives you a number to bring to the appointment and informs the conversation about whether treatment is indicated.
What actually helps — evidence graded
💊
HRT — the most effective bone protection at menopause
Strong evidence
HRT is the most evidence-backed intervention for preventing bone loss at menopause. It directly addresses the primary cause — estrogen deficiency — and multiple large studies confirm it reduces fracture risk by 30-50%. The WHI study, despite its other limitations, confirmed significant hip fracture reduction in HRT users. The effect begins within 1-2 years of starting and is maintained as long as HRT continues.
Key points
• Reduces vertebral fracture risk by 35-40% and hip fracture risk by 25-30% in RCTs
• Prevents the 2-4% annual bone loss of the menopausal transition
• Effect begins rapidly — measurable bone density improvement within 12-24 months
• Endorsed by IOF, NAMS, BMS, and NICE as effective bone protection at menopause
• Women who stop HRT experience accelerated bone loss — tapering rather than abrupt cessation is preferable
How to use this
Standard transdermal HRT (estradiol with micronised progesterone if uterus intact). Bone protection benefit occurs at standard doses used for symptom control — no additional dose is needed for bone specifically. Continued use provides continued protection. Request DEXA scan 2-3 years after starting to confirm the expected benefit.
🏋️
Resistance training — the non-negotiable bone intervention
Strong evidence
Mechanical loading through resistance training is the most powerful non-hormonal stimulus for bone formation. Osteoblasts are mechanosensitive — they respond to the forces transmitted through bone during resistance exercise by producing new bone matrix. High-impact activities (jumping, skipping) are also potent bone stimulators. Endurance exercise alone (walking, cycling) provides minimal bone benefit.
Key points
• The LIFTMOR trial showed high-intensity resistance training increased lumbar spine density by 2.9% and femoral neck by 0.3% — significant reversal of expected loss
• Reduces fall risk by improving balance, coordination, and muscle strength
• Progressive loading is required — the stimulus must increase over time
• Both spine and hip bone density improve with targeted resistance training
• Effect is site-specific — exercises must load the spine and hip to protect those sites
How to use this
Minimum 2-3 sessions weekly. Include: squats, deadlifts, lunges (hip loading), rows and overhead press (spine loading through axial forces). High impact: jumping jacks, skipping, heel drops (rising on toes then dropping onto heels — simple and effective). Progress weight regularly — the loading must be progressive to continue stimulating bone formation. See the exercise guide for the full framework.
☀️
Vitamin D — optimise, not just correct deficiency
Strong evidence
Vitamin D is essential for calcium absorption from the gut — without adequate vitamin D, only 10-15% of dietary calcium is absorbed. At optimal vitamin D levels (60-80 ng/mL / 150-200 nmol/L), absorption rises to 30-40%. Standard supplementation advice (400-800 IU) maintains sufficiency but rarely achieves optimal levels for bone protection. Most perimenopausal women need 2000-4000 IU daily to reach the optimal range — testing and titrating to the target is more reliable than standard dosing.
Key points
• Without adequate vitamin D, calcium supplementation has minimal bone benefit
• Optimal levels (60-80 ng/mL) required for maximum calcium absorption
• Reduces fall risk — vitamin D supports muscle function and neuromuscular coordination independently
• Meta-analyses show combined vitamin D + calcium reduces fracture risk by 15-20%
How to use this
Test 25-OH vitamin D. Standard laboratory "sufficient" is above 50 nmol/L — but the bone-protective optimal is 60-80 ng/mL (150-200 nmol/L). Most women need 2000-4000 IU vitamin D3 daily to reach this range. Retest in 3 months after dose change. Take with K2 (MK-7 form, 100-200 µg) — K2 directs calcium into bone rather than arteries.
🥛
Calcium — from food first, supplement strategically
Strong evidence
Calcium is the primary mineral of bone matrix — 99% of the body's calcium is in bones and teeth. The recommended intake increases from 700mg to 1000-1200mg daily at menopause. Food sources are preferable to supplements — calcium from food is better absorbed and does not carry the modest cardiovascular risk signal associated with high-dose calcium supplements.
Key points
• Adequate calcium prevents the body drawing calcium from bone to maintain blood levels
• Combined with vitamin D, reduces fracture risk meaningfully
• Food sources (dairy, leafy greens, fortified foods, tinned fish with bones) provide calcium in conjunction with other bone-supporting nutrients
• Supplemental calcium above 500mg per dose has reduced absorption — split doses if supplementing
How to use this
Prioritise dietary calcium: 3 portions of dairy daily (or equivalent) provides approximately 900mg. Leafy greens (kale, broccoli, bok choy — not spinach, which binds calcium), fortified plant milks, tinned sardines/salmon with bones, almonds. If dietary intake is below 800mg, supplement the deficit — calcium citrate is better absorbed than carbonate, especially if stomach acid is reduced.
🔶
Bisphosphonates — when bone density is already low
Strong evidence
Bisphosphonates (alendronate, risedronate, zoledronic acid) inhibit osteoclast activity — directly reducing bone resorption. They are the most prescribed pharmaceutical treatment for established osteoporosis and osteopenia with high fracture risk. Unlike HRT, they do not address the hormonal cause but directly reduce the rate of bone breakdown. They can be used alongside HRT or as an alternative for women who cannot take HRT.
Key points
• Alendronate reduces vertebral fracture risk by 45-50% and hip fracture by 40-50% in RCTs
• Weekly oral dosing (alendronate) or annual IV infusion (zoledronic acid) — different compliance profiles
• Continue for 5-10 years depending on fracture risk and DEXA response
• The benefit persists for some years after stopping — bone is stored
How to use this
Prescription required. Discussed with GP when DEXA shows T-score below -2.0 or -1.5 with additional risk factors. Important to take correctly: alendronate on an empty stomach with a full glass of water, remain upright for 30 minutes. Not suitable if poor kidney function or oesophageal problems. Annual DEXA monitoring to assess response.
🥩
Protein and collagen — the bone matrix that calcium fills
Moderate evidence
Bone matrix is not just calcium — it is 30% collagen, which provides the flexible scaffold that gives bone its fracture resistance. Low protein intake reduces collagen synthesis and bone quality even when mineral density is maintained. Hydrolysed collagen supplementation has growing evidence for improving bone density and bone quality specifically.
Key points
• Adequate protein (1.2-1.6g/kg) supports both bone collagen synthesis and muscle mass
• Hydrolysed collagen peptides 10g daily — specific evidence for vertebral bone density improvement
• Vitamin C is the cofactor for collagen synthesis — 500mg-1g daily supports bone matrix production
• High protein does not leach calcium from bones — the acid-load theory has been disproven. Higher protein improves bone outcomes.
How to use this
Prioritise protein at every meal. Collagen peptide powder 10g daily in coffee, smoothies, or soup — Vital Proteins, Ancient + Brave, or similar quality products. Vitamin C 500mg daily with collagen for synthesis cofactor support.
What to say to your doctor
Asking for bone protection proactively
"I am in perimenopause and I would like to be proactive about bone health. I have [early menopause / surgical menopause / family history / have been on corticosteroids / am underweight] — can I have a DEXA scan to establish my baseline bone density?"
"I would like to discuss HRT as bone protection specifically, in addition to my other menopause symptoms. I understand it reduces hip fracture risk by 25-30% and vertebral fracture by 35-40%."
"My vitamin D came back as 42 nmol/L — within the laboratory reference range but below the 60-80 ng/mL optimal for bone protection. I would like to supplement to optimise this and retest in 3 months."
Rose on this
"Bone loss is the menopause consequence that hides completely until something breaks. By the time a fracture happens, years of preventable loss have already occurred. The five-year window around menopause is when this is most reversible — when HRT and resistance training and vitamin D optimisation make the largest difference. Act now, not after the DEXA comes back low. The best time to protect your bones was before menopause. The second best time is today."
From Rose
"Strong bones at 70 are built in your 40s and 50s. The actions you take in this window compound over decades. Resistance training builds bone — and keeps building it as long as you keep training. HRT protects what you have. Vitamin D and calcium give the raw materials. These are not complicated or expensive. They are just decisions. Make them now."
What we do not know yet
?The optimal duration of HRT for bone protection and whether there is a threshold below which stopping HRT accelerates bone loss to above baseline rates — current data suggests some residual benefit persists after stopping but the duration effect is unclear
?Whether combining HRT with bisphosphonates provides additive benefit beyond either alone — the data is limited and combination is not currently standard practice
?The minimum effective dose of resistance training for bone protection specifically in postmenopausal women — the LIFTMOR trial used high-intensity protocols that may not be accessible or safe for all women, and lower-intensity equivalents have less evidence
Written by
Rose
Navigating perimenopause · Researcher · Founded rosemyfriend.com
Research basis
PubMed · Cochrane reviews · NICE guidelines · British Menopause Society · The Menopause Society
Read methodology →
Rose provides evidence-graded educational information — not medical advice. Always discuss health decisions with a qualified healthcare provider.
Full disclaimer ·
About Rose